search
Back to results

Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma (GBM)

Primary Purpose

Glioblastoma

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
New delineation approach
Sponsored by
Zhongnan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glioblastoma focused on measuring Radiotherapy, clinical target volume, Glioblastoma multiforme (GBM), radiation volume, the white matter tracts.

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 18-70 years
  • performance status of 0-1 (Eastern Cooperative Oncology Group performance status)
  • histologically confirmed glioblastoma
  • no cerebrospinal fluid and distant metastatic disease
  • All patients had adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

  • younger than 18 years;
  • patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    New delineation approach (NDA)group

    Arm Description

    use a new method for clinical target volume delineation by referencing the nerve fiber bundles

    Outcomes

    Primary Outcome Measures

    Overall survival (OS)
    Time from the start of treatment to death due to the disease

    Secondary Outcome Measures

    recurrence-free survival (RFS)
    Time from the start of treatment to recurrence

    Full Information

    First Posted
    August 16, 2022
    Last Updated
    August 22, 2022
    Sponsor
    Zhongnan Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05512195
    Brief Title
    Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma
    Acronym
    GBM
    Official Title
    Safety and Efficacy of a New Approach to Delineating Clinical Target Volume by Referencing the Nerve Fiber Bundles for Radiotherapy of Glioblastoma
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 1, 2022 (Anticipated)
    Primary Completion Date
    September 1, 2024 (Anticipated)
    Study Completion Date
    August 31, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Zhongnan Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Radiotherapy (RT) is one of the most important local treatments besides surgery, but currently, no consensus has been made regarding the optimal radiation volume for high grade gliomas. The most main growth characteristics of glioblastoma is infiltrative growth through the white matter tracts, regions along the white matter tracts especially at the direction of the main fiber bundles would have a higher risk of microscopic tumor cell dissemination. However, in current practice, recommends for the CTV definition is adding a 2 cm symmetrical margin to GTV or peritumoral edema in all directions, which hardly account for the growth characteristics of gliomas that are known from histopathological findings.
    Detailed Description
    Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded. Eligible patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen(75mg/m2 per day during RT), followed by 6 additional cycles of TMZ. (150 mg/m2 for the first cycle and 200 mg/m2 for the 2-6th cycles, on days 1-5, every 4 weeks) . The investigators established a detailed protocol for target delineation of the CTV based on brain anatomy, white mater fiber tracts distribution and the growth patterns of tumor. Briefly, along the directions of the main nerve fiber bundles ,the CTV is defined as peritumoral edema plus 1cm. while in other directions, the CTV is defined as GTV plus 2cm and should be adjusted to anatomical borders such as the skull (0 mm, using bone window), ventricles (5 mm), falx (0 mm), tentorium cerebelli (0 mm), visual pathway/optic chiasm and brainstem (each 0 mm) and modified to include all regions of abnormal T2/FLAIR MRI signal. Deep brain white matter is the focus for RT target contour, regions of normal uninvolved gray matter should be modified to be protected.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Glioblastoma
    Keywords
    Radiotherapy, clinical target volume, Glioblastoma multiforme (GBM), radiation volume, the white matter tracts.

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    70 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    New delineation approach (NDA)group
    Arm Type
    Experimental
    Arm Description
    use a new method for clinical target volume delineation by referencing the nerve fiber bundles
    Intervention Type
    Radiation
    Intervention Name(s)
    New delineation approach
    Intervention Description
    New delineation approach
    Primary Outcome Measure Information:
    Title
    Overall survival (OS)
    Description
    Time from the start of treatment to death due to the disease
    Time Frame
    2 years
    Secondary Outcome Measure Information:
    Title
    recurrence-free survival (RFS)
    Description
    Time from the start of treatment to recurrence
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age between 18-70 years performance status of 0-1 (Eastern Cooperative Oncology Group performance status) histologically confirmed glioblastoma no cerebrospinal fluid and distant metastatic disease All patients had adequate hematologic, hepatic, and renal function. Exclusion Criteria: younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma

    We'll reach out to this number within 24 hrs